18:I[66739,["/_next/static/chunks/0u0nyy7wb9me2.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/05hx6kuf6-oy4.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/12hmyxte1w1dw.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/166.u_60qj09..js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/0g9_wl34k-6l4.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/06dn~uer6.43l.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i"],"default"] 1a:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_EVxQmm5ee6SfSwpTLEi7dkcqj48i"],"IconMark"] 19:T523,

Christine Short and Scott Zari cover Eli Lilly (LLY) earnings and the future of GLP-1 drugs. Christine emphasizes the global demand for these drugs, as evidenced by higher international revenue, and what a daily oral GLP-1 pill could do for the company. Scott looks at Eli Lilly’s market share in the weight loss sector, calling it a “two horse race” between them and Novo Nordisk (NVO).

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

About Schwab Network - https://schwabnetwork.com/about

LLY Earnings: How an Oral GLP-1 Pill Could Supercharge Revenue

Schwab Network

LLY Earnings: How an Oral GLP-1 Pill Could Supercharge Revenue